Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following... see more

Recent & Breaking News (TSXV:NRX)

NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets

GlobeNewswire 7 days ago

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

GlobeNewswire November 1, 2024

NurExone's Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA

GlobeNewswire October 23, 2024

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

GlobeNewswire September 26, 2024

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences

GlobeNewswire September 12, 2024

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study

GlobeNewswire September 6, 2024

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 28, 2024

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences

GlobeNewswire August 23, 2024

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

GlobeNewswire August 15, 2024

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites - New Study

GlobeNewswire August 9, 2024

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer

GlobeNewswire August 1, 2024

NurExone Announces Further Expansion of ExoPTEN Patent Coverage

GlobeNewswire July 29, 2024

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone's first product ExoPTEN for Glaucoma

GlobeNewswire July 17, 2024

Updates from NurExone: Growth Conference Presentation and Website Relaunch

GlobeNewswire July 5, 2024

New treatment studied in $3.4 billion glaucoma market

Jonathon Brown July 3, 2024

NurExone's ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

GlobeNewswire June 28, 2024

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

GlobeNewswire June 21, 2024

NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application

GlobeNewswire June 11, 2024

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders

GlobeNewswire June 4, 2024

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

GlobeNewswire May 29, 2024